Canada: Healthcare

Le CEPMB a publié son édition de septembre 2026 de la Nouvelle, annonçant des nominations clés et détaillant le premier engagement pris sous les nouvelles Lignes directrices concernant IMCIVREE de Rhythm Pharmaceuticals.

Santé Canada a publié les résultats de sa consultation sur la modernisation du cadre des essais cliniques et annonce une politique provisoire qui introduit des changements importants concernant les approbations éthiques, la définition de chercheur qualifié et les méthodes de consentement éclairé. Ces modifications entreront en vigueur progressivement jusqu'au printemps 2028, avec la publication finale de la réglementation prévue pour le printemps 2027.

The founders of the Drug User Liberation Front (DULF) have won a major constitutional challenge against the Controlled Drugs and Substances Act, which prohibited the implementation of their non-medicalized safer supply program in the context of the toxic drug crisis.

It builds on the CDA’s 2025 Position Statement on the Use of Artificial Intelligence and was adapted from guidance published by the United Kingdom’s National Institute for Health and Care Excellence (“NICE”). While the CDA does not prohibit the use of AI, its overall position is cautious: AI should generally supplement, not replace, established methods.

Artificial intelligence is transforming healthcare delivery in Ontario, but its integration raises critical questions about patient privacy, legal compliance, and human rights protections.

Effective October 1, 2026, important changes will be implemented through Bill 11, the Health Statutes Amendment Act, 2025 (No. 2), that will have immediate implications for Alberta employers.

Santé Canada a lancé un nouveau portail de recherche des essais cliniques et publié une ligne directrice mise à jour sur l'enregistrement et la divulgation des résultats.

Osler's Legislative Update is a bi-weekly listing of new legislation. This issue covers legislation for the period 08/06 to 08/19.

Health Canada has secured a permanent injunction against Canlab Research, a Quebec-based online retailer, preventing the company from manufacturing, distributing, or selling unauthorized injectable peptides in Canada. This enforcement action follows years of regulatory warnings and provisional court orders aimed at stopping the illegal sale of peptide drugs promoted with unproven health claims for anti-aging, weight loss, and athletic performance.